Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond

Surg Oncol Clin N Am. 2002 Jul;11(3):571-88, vi. doi: 10.1016/s1055-3207(02)00043-1.

Abstract

Loss of p53 function is one of the most frequent genetic alterations in human cancers. Both replication-incompetent (rAd.p53, or SCH58500) and replication-selective (dl1520, or Onyx-015) adenoviruses are being developed for the treatment of p53-deficient cancers. Hepatic arterial infusion (HAI) has historically been used to selectively target colorectal tumors within the liver; consequently, regional therapy with adenovirus in this setting is an attractive approach. This article reviews Phase I and I/II HAI trial results with these adenovirus constructs.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Colorectal Neoplasms / pathology*
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Gene Transfer Techniques* / adverse effects
  • Gene Transfer Techniques* / trends
  • Genes, p53 / genetics*
  • Genetic Therapy / adverse effects
  • Genetic Therapy / methods*
  • Genetic Therapy / trends
  • Genetic Vectors / therapeutic use*
  • Hepatic Artery
  • Humans
  • Infusions, Intra-Arterial
  • Liver Neoplasms / genetics
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy*
  • Maximum Tolerated Dose
  • Viral Vaccines / pharmacokinetics
  • Viral Vaccines / therapeutic use*

Substances

  • Viral Vaccines
  • dl1520